Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 62-68 , January 2001

The palliative management of skeletal metastases in prostate cancer: Use of bone-seeking radionuclides and bisphosphonates

  • Neveen A.T. Hamdy

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Neveen A.T. Hamdy, MD, MRCP, Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
    • ,
  • Socrates E. Papapoulos

References 

  1. Schroder FH. Endocrine treatment of prostate cancer. In: Walsh PC, Retik AB, Vaughan ED, et al. editor. Campbell's Urology. Philadelphia, PA: Saunders; 1998;p. 2627–2644
  2. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88(suppl):3009–3014
  3. Benson RC, Hasa SM, Jones AG, et al. External beam radiotherapy for palliation of pain for metastatic carcinoma of the prostate. J Urol. 1982;127:69–71
  4. Epstein LM, Steward BH, Antunez AR, et al. Half and total body radiation for carcinoma of the prostate. J Urol. 1979;122:330–332
  5. Salazar OM, Rubin P, Hendrickson FR, et al. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Cancer. 1986;58:29–36
  6. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases. Cancer. 1982;50:893–899
  7. Payne R. Pain management in the patients with prostate cancer. Cancer. 1993;71(suppl):1131–1137
  8. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain. 1997;69:1–18
  9. McEwan AJB. Unsealed source therapy of painful bone metastases: An update. Semin Nucl Med. 1996;27:165–182
  10. McEwan AJB, Amyotte GA, McGowan DG, et al. A retrospective analysis of the cost-effectiveness of treatment with Metastron R (89Sr-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun. 1994;15:499–504
  11. Silberstein EB, Elgazzar AH, Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992;22:17–27
  12. Ben-Josef E, Lucas DR, Vasan S, et al. Selective accumulation of strontium-89 in metastatic deposits in bone: Radiohistologic correlation. Nucl Med Commun. 1995;16:457–463
  13. Blake GM, Zivanovic MA, Blaquiere RM, et al. Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549–557
  14. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine-resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805–813
  15. Robinson RG, Preston DF, Schiefelbein M, et al. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995;274:420–424
  16. Paszkowski AL, Hewitt DJ, Taylor A. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate. Clin Nucl Med. 1999;24:852–854
  17. Dearnaley DP, Bayly RJ, A'Hern RP, et al. Palliation of bone metastases in prostate cancer: Hemibody irradiation or Strontium-89?. Clin Oncol. 1992;4:101–107
  18. Mertens WC. Radionuclide therapy of bone metastases: Prospects for enhancement of therapeutic efficacy. Semin Oncol. 1993;20(suppl 2):49–55
  19. Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89. Nucl Med Commun. 1996;17:799–804
  20. (abstr) Dahut W, Arcenas A, Feldman S, et al. Strontium-89 (Sr-89 Metastron®) and estramustine (EM) in hormone refractory prostate cancer (HRPC): A phase II study. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 16:1997;p. 331
  21. (abstr) Wehbe T, Akerley W, Stein B, et al. Strontium-89, estramustine and vinblastine (SEV) in hormone refractory prostate carcinoma (HRPC): Concurrent chemoradiotherapy. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 16:1997;p. 312
  22. Maxon HR, Schroder LE, Thomas SR, et al. RE-186 (Sn) HEDP for treatment of painful osseous metastases: Initial experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990;176:155–159
  23. Quirijnen JMSP, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 1996;37:1511–1515
  24. Serafini AN. Samarium Sm-153 Lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88:2934–2939
  25. Frith JC, Monkkonen J, Blackburn GM, et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-b, g-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1998;12:403–408
  26. Russell RGG, Rogers MJ, Frith JC, et al. The pharmacology of bisphosphonates and new insights into their mechanism of action. J Bone Miner Res. 1999;14(suppl 2):56–65
  27. Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-transnational prenylation of GTP-binding proteins including Ras. J Bone Miner Res. 1998;13:581–589
  28. Van Beek E, Lowik C, van der Pluijm G, et al. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res. 1999;14:722–729
  29. Van Beek E, Pieterman E, Cohen L, et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999;255:491–494
  30. Van Beek E, Pieterman E, Cohen L, et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun. 1999;264:108–111
  31. Fisher JE, Rogers MJ, Halasy JM, et al. Mechanism of action of alendronate: Geranylgeraniol, an intermediate of the mevalonate pathway prevents inhibition of osteoclast formation, bone resorption and kinase activity in vitro. Proc Natl Acad Sci USA. 1999;96:133–138
  32. Mundy GR. Mechanisms of bone metastasis. Cancer. 1997;80(suppl 8):1546–1556
  33. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–572
  34. Oft M, Heider KH, Beug H. TGF-β signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol. 1998;8:1243–1252
  35. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140:4451–4458
  36. Koutsilieris M. Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. 1993;13:443–449
  37. Koutsilieris M, Frenette G, Lazure C, et al. Urokinase-type plasminogen activator: A paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. 1993;13:481–486
  38. Goltzman D. Mechanisms of the development of osteoblastic metastases. Cancer. 1997;80(suppl):S1581–S1587
  39. Autzen P, Robson CN, Bjartell A, et al. Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br J Cancer. 1998;78:1219–1223
  40. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995;1:944–949
  41. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology. 1999;53:1063–1069
  42. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate. 2000;44:77–87
  43. Charhon SA, Chapuy MC, Delvin EE, et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia. Cancer. 1983;51:918–924
  44. Urwin GH, Pervical RC, Harris S, et al. Generalized increase in bone resorption in carcinoma of the prostate. Eur J Urol. 1985;57:721–723
  45. Percival RC, Urwin GH, Harris S, et al. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol. 1987;13:41–49
  46. Clarke NW, McClure J, George NJR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68:74–80
  47. Taube T, Kylmala T, Lamberg-Allardt C, et al. The effect of clodronate on bone in metastatic prostate cancer. Histomorphometric report of a double blind randomized placebo-controlled study. Eur J Cancer. 1994;30:751–758
  48. Ikeda I, Miura T, Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 1996;77:102–106
  49. Maeda H, Koizumi M, Yoshimura K, et al. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 1997;157:539–543
  50. Pelger RCM, Hamdy NAT, Zwinderman AH, et al. Effects of the bisphosphonate olpadronate in patients with. Bone. 1998;22:403–408
  51. Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345–357
  52. Papapoulos SE, Hamdy NAT, van der Pluijm G. Bisphosphonates in the management of prostatic carcinoma metastatic to the skeleton. Cancer. 2000;88:3047–3053
  53. Lipton A. Bisphosphonates and breast carcinoma. Cancer. 2000;88:3033–3037
  54. Kanis JA, McCloskey EV. Bisphosphonates in multiple myeloma. Cancer. 2000;88:3022–3032
  55. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol. 1998;16:1218–1225
  56. Carey PO, Lippert MC. Treatment of painful prostatic bone metastases with oral etidronate disodium. Urology. 1988;32:403–407
  57. Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double blind, placebo-controlled study. J Urol. 1989;141:85–87
  58. Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985;134:1152–1154
  59. Adami S, Mian M. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma. Recent Results Cancer Res. 1989;116:67–72
  60. Vorreuther R. Bisphosphonates as an adjunct to palliative therapy of bone metastases from prostatic carcinoma. A pilot study on clodronate. Br J Urol. 1993;72:792–795
  61. Cresswell SM, English PJ, Hall RR, et al. Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer. Br J Urol. 1995;76:360–365
  62. Elomaa I, Kylmala T, Tammela T, et al. Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostatic cancer. Int Urol Nephrol. 1992;24:159–166
  63. Masud T, Slevin ML. Pamidronate to reduce bone pain in normocalcaemic patient with disseminated prostatic carcinoma. Lancet. 1989;1:1021–1022
  64. Pelger RCM, Lyclama à Nijeholt AAB, Papapoulos SE. Short-term metabolic effects of pamidronate in patients with prostatic carcinoma and bone metastases. Lancet. 1989;2:865
  65. Clarke NW, McClure J, George JR. Morphometric evidence for bone resorption and replacement in prostate cancer. Br J Urol. 1991;68:74–80
  66. Clarke NW, McClure J, George NJR. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer. Br J Urol. 1992;69:64–70
  67. Lipton A, Glover D, Harvey H, et al. Pamidronate in the treatment of bone metastases: Results of 2 dose-ranging trials in patients with breast or prostate cancer. Ann Oncol. 1994;5(suppl 7):S31–S35
  68. Kanis JA, Powles T, Paterson AHG, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663–667
  69. Diel I, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357–363
  70. (abstr) Powles TJ, Paterson AHG, Nevantaus S, et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 17:1998;p. 123
  71. (abstr) Saarto T, Bloomquist V, Virkkunen P, et al. No reduction of bone metastases with adjuvant clodronate treatment in node positive breast cancer patients. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 17:1998;p. 123
  72. Yoneda T, Michigami T, Yi B, et al. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000;88(suppl):2979–2988
  73. Van der Pluijm G, Vloedgraven H, van Beek E, et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest. 1996;98:98–705
  74. Boissier S, Magnetto S, Frappart L, et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 1997;57:3890–3894
  75. Teronen O, Heikkila P, Konttinen YT, et al. MMP inhibition and down regulation by bisphosphonates. Ann N Y Acad Sci. 1999;878:453–465
  76. Cook GJR, Fogelman I. The role of positron emission tomography in the management of bone metastases. Cancer. 2000;88(suppl):S2927–S2933

PII: S0001-2998(01)80032-5

doi: 10.1053/snuc.2001.18767

Seminars in Nuclear Medicine
Volume 31, Issue 1 , Pages 62-68 , January 2001

Article Tools